|
|
 |
|
Viewing report
|
|
|
|
The CNS Market Outlook to 2012
Business Insights, Oct 2007, Pages: 280
CNS disorders constitute one of the most significant components of healthcare spending in the developed world, contributing to an estimated 35% of the disease burden within the seven major pharma markets. However, an increased presence of generic products and lack of innovative product launches have prompted a slowdown in market growth, which pharma and biotech companies are addressing through a shift in R&D focus towards disease areas with relatively low levels of innovation, such as Alzheimer’s and Parkinson’s disease.
‘The CNS Market Outlook to 2012’ is a new report that provides a detailed epidemiological analysis of major indications within the CNS disorders market, and examines the factors impacting their prevalence. The current opportunities and threats facing the market are assessed and the most promising potential growth areas across all indications are highlighted. The report also profiles the key trends influencing treatment sales and analyses the competitive dynamics of leading brands within each indication. Discover the key trends and growth drivers within the CNS market, assess the competitive dynamics of leading pharma companies and evaluate the future prospects of major products with this new report...
Use this report as a platform to…
-Assess the patient potential of major CNS indications within key markets including Japan, France, Germany, Italy, Spain, the UK and the US.
-Measure the market performance and strategic positioning of major pharmaceutical corporations including J&J, Pfizer, GSK, Sanofi-Aventis, Novartis, Forest, Wyeth, Lilly and AstraZeneca.
-Understand the market dynamics of the CNS therapeutic area by using this report’s detailed analysis of major market trends and growth drivers.
-Compare the franchises and future prospects of key players across major indications with this report’s close examination of currently marketed portfolios, R&D pipelines, and trends in promotional spend for major brands.
-Identify the strategies that offer the greatest success potential within the future CNS Disorders Market and understand the challenges currently facing companies within this therapeutic area.
Some Key Findings From This Report...
-Alzheimer’s disease is forecast to be the primary driver of growth within the CNS market over the 2006-12 period, with a CAGR of 13.1%. Factors driving this growth include new product launches and the implementation of strategies to protect revenue streams.
-The leading nine companies’ CNS portfolios recorded a growth rate of 7.0% in 2005-6, representing sales of $57.9m. However, sales have become increasingly volatile due to recent patent expiries.
-Five of the most promising compounds identified by this report are replacements for blockbusters that are forecast to lose patent protection by 2012. These include J&J’s Invega (paliperidone), Wyeth’s DVS-233 and Merck’s potential anti-depressant Vilazodone.
-Pfizer continues to face substantial revenue losses as a result of significant generic competition, however sales of Lyrica are forecast to reinforce the company’s portfolio growth over the 2006-12 period.
-Heavy genericization will cause epilepsy to become a fiercely contested market. Major companies have begun to explore new strategies and indications in an effort to protect sales revenues.
Top Five Reasons To Order Your Copy Today
-Assess the patient potential of major CNS indications within key markets including Japan, France, Germany, Italy, Spain, the UK and the US.
-Measure the market performance and strategic positioning of major pharmaceutical corporations including J&J, Pfizer, GSK, Sanofi-Aventis, Novartis, Forest, Wyeth, Lilly and AstraZeneca.
-Discover the market dynamics of the CNS therapeutic area by using
this report’s detailed analysis of major market trends and growth drivers.
-Compare the franchises and future prospects of key players across major indications with this report’s close examination of currently marketed portfolios, R&D pipelines, and trends in promotional spend for major brands.
-Identify the strategies that offer the greatest success potential within the future CNS Disorders Market and understand the challenges currently facing companies within this therapeutic area.
Key Issues Examined In This Report...
-Increasing patient population. Physicians and patients are becoming increasingly aware of CNS disorders as the numbers of those afflicted by such conditions continues to rise. This is helping to gradually erode the social stigma attached to the diseases.
-Lifecycle extension/Generics strategies. Imminent patent expiries for major brands have resulted in companies investigating new indications and re-formulation strategies to extend patent validity and safeguard revenue streams. Companies have also begun to
manufacture and market generic versions of their products, a notable example of which is Pfizer’s launch of Gabapentin to replace Neurontin
-Alzheimer’s market potential. Therapies indicated for the treatment of AD feature the strongest growth prospects, due to a high level of unmet need, moderate genericization and new drug classes.
-CNS franchise challenges. Franchise sales across major therapy areas continue to be threatened by negative events associated with SSRI’s. Recent withdrawals of pergolide-based products and unscheduled releases of negative clinical data have also jeopardized sales potential.
Your questions answered...
-Which indications will experience the greatest growth in the CNS disorders market over the period 2006-12?
-Who were the CNS market’s best and worst performing companies in 2006?
-To what extent does generic competition threaten the performance of migraine, schizophrenia and epilepsy markets?
-Which companies are best positioned for future success in the CNS disorders market?
-How will generic competition influence the future of branded products and which defensive strategies provide the most effective protection?
-Which pipeline products offer the highest growth potential?
-What will be the competitive landscape for major sub-indications of depression, schizophrenia, AD, PD and migraine in 2012?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
The CNS Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
The CNS Market 2008 Report
The CNS Market Outlook to 2010
Commercial Insight: CNS Market Overview - Commercial Dynamics And Outlook Of The Neurology, Pain And Psychiatry Market Sectors
CNS Therapeutics - Global Strategic Business Report
CNS Therapeutics - A World Market Review
CNS Therapeutics - A World Market Review
CNS Drug Discoveries: Schizophrenia Chapter
The CNS Market Outlook to 2011
Pipeline Insight: Orphan Diseases in CNS - Part II: Amyotrophic Lateral Sclerosis
Pipeline Insight: Orphan Diseases in CNS - Part I: Huntingtons Disease
Lifestyle Drugs Market Outlook: Key Indications, Epidemiology, and Emergent Drugs
|
|
|
|
